Temsirolimus as Second-line Therapy in HCC

A Phase II Study of Temsirolimus as Second-line Therapy in Patients With Advanced, Unresectable Hepatocellular Carcinoma

NCT01567930•University of Tennessee Cancer Institute

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Unresectable or Metastatic Hepatocellular Carcinoma

Interventions

Temsirolimus

Locations

United States

Locations (1)

Boston Baskin Cancer Foundation

Memphis, Tennessee, United States

Key Dates

Start Date

February 1, 2010

Primary Completion Date

December 1, 2012

Completion Date

March 1, 2013

Last Updated

December 17, 2012

Contacts

Steve West, BS, CCRP

CONTACT

901.226.1493 steve.west@bmhcc.org

Sponsors

Lead Sponsor

University of Tennessee Cancer Institute

Collaborators

Wyeth is now a wholly owned subsidiary of Pfizer

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 17, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions